Suzhou Ronnsi Biotechnology Co., Ltd. was founded in November 2012, with focus on complex drug research and development through integration of chemistry, biology, enzyme technology, analytical techniques, and bioinformatics.This platform technology has enabled us to develop several complex generic drugs such as enoxaparin, Copaxone and Abraxane. It also led us to discover and develop the novel drug candidate, dHG.Collaborating with world renewed expertise and leading Institute in heparin chemistry and biology, Professor Jawed Fareed, professor Robert Linhardt, and Ronzoni Institute, We have developed the first non-porcine based enoxaparin--ovine enoxaparin, Ronnsi is planning to file ovine enoxaparin NDA in USA and Indonesia in the next 2 years. We have made a substantial investment in analytics and characterization technology. Our quality control lab has passed audit from a US pharmaceutical company and is ISO9001 certified. Our long term goal is to continue pushing our science forward to develop products that create value for patients and our shareholders.